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1	  
List	  of	  Abbreviations	  
AS	   	  	  	  	  	  	  	  Anticholinergic	  and	  Sedative	  	  
AOR	   	  	  	  	  	  	  	  Adjusted	  Odds	  Ratio	  
ATC	   	  	  	  	  	  	  	  Anatomical	  Therapeutic	  Chemical	  -­‐	  Classification	  System	  	  
BPPV	   	  	  	  	  	  	  	  Benign	  paroxysmal	  positioning	  vertigo	  
CI	   	  	  	  	  	  	  	  Confidence	  Interval	  
CONTENT	   	  	  	  	  	  	  	  CONTinuous	  morbidity	  registration	  Epidemiologic	  NeTwork	  
DBI	   	  	  	  	  	  	  	  Drug	  Burden	  Index	  
DDD	   	  	  	  	  	  	  	  Defined	  Daily	  Dose	  
DIMDI	   	  	  	  	  	  	  	  Deutsches	  Institut	  für	  Medizinische	  Dokumentation	  und	  Information	  
	  	  	  	  	  	  	  (German	  Institute	  of	  Medical	  Documentation	  and	  Information)	  
ICD-­‐10	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  International	  Classification	  of	  Diseases	  10th	  Revision	  
KORA	   	  	  	  	  	  	  	  Kooperative	  Gesundheitsforschung	  in	  der	  Region	  Augsburg	  
	  	  	  	  	  	  	  (Cooperative	  Health	  Research	  in	  the	  Region	  of	  Augsburg)	  
PCP	   	  	  	  	  	  	  	  Primary	  Care	  Practitioners	  
VDB	   	  	  	  	  	  	  	  Vertigo,	  Dizziness	  and	  Balance	  disorders	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Doctoral	  Thesis:	  THE	  IMPACT	  OF	  ANTICHOLINERGIC	  AND	  
SEDATIVE	  MEDICATIONS	  ON	  VERTIGO,	  DIZZINESS	  AND	  
BALANCE	  DISORDERS	  IN	  OLDER	  PEOPLE	  IN	  GERMANY	  
	  
Introductory	  Summary:	  	  
Relevance/Problem	  Statement	  
Advancements	  in	  health	  care	  have	  provided	  people	  the	  opportunity	  to	  add	  life	  to	  years	  
and	  not	   just	   years	   to	   life.	  Consequently,	  due	   to	   the	  progressive	  demographic	   shift,	   the	  
population	  is	  gradually	  aging	  and	  are	  more	  susceptible	  to	  chronic	  diseases,	  adverse	  drug	  
reactions,	  polypharmacy	  and	  comorbidity.	  According	  to	  the	  World	  Health	  Organization,	  
by	  2050	  it	  is	  estimated	  that	  every	  1	  in	  5	  people	  will	  be	  60	  years	  or	  older	  and	  account	  for	  
about	  half	  of	  the	  total	  growth	  of	  the	  world	  population	  (1,	  2).	  Additionally,	  the	  oldest-­‐old	  
population	  (≥85	  years	  old)	  accounts	  for	  a	  majority	  of	  health	  care	  spending	  in	  Europe	  (3-­‐
5).	   In	   Germany,	   5%	   of	   health	   care	   users	   and	   over	   30%	   of	   medication	   costs	   can	   be	  
contributed	   to	   older	   people	  with	   comorbidities	   (4).	   As	   life	   expectancies	   increase	  with	  
modern	  times,	  the	  challenge	  faced	  is	  the	  older	  population	  battling	  with	  chronic	  diseases	  
all	   the	  while	  being	  very	  dependent	  on	  the	  health	  care	  system	  to	  conserve	  and	  prolong	  
their	  quality	  of	  life	  (6).	  	  	  
Vertigo,	  dizziness	  or	  balance	  disorders	  (VDB)	  are	  among	  the	  most	  prevalent	  causes	  for	  
falls	  (7)	  and	  among	  the	  most	  disabling	  symptoms	  in	  older	  people	  (8).	  Yearly,	  VDB	  was	  
found	  to	  affect	  around	  15	  to	  over	  20%	  of	  adults	  in	  large	  population-­‐based	  studies	  and	  its	  
prevalence	  rises	  with	  age	  (9)	  reaching	  up	  to	  85%	  in	  those	  ≥80	  years	  old	  (7).	  In	  Germany,	  
lifetime	  prevalence	  of	  vertigo	  and	  dizziness	  in	  community-­‐dwelling	  adults	  was	  found	  to	  
be	   29.3%	   (women:	   35.9%,	   men:	   22.6%)	   (9-­‐11).	   Furthermore,	   a	   recent	   age	   and	   sex	  
representative	  survey	  of	  the	  German	  population,	  found	  an	  overall	  1-­‐year	  prevalence	  of	  
vertigo	  or	  dizziness	  to	  be	  24.2%	  (12).	  In	  Bavaria,	  annually	  10%	  of	  the	  adult	  population	  
is	  diagnosed	  and	  treated	  for	  vertigo	  (13,	  14).	  VDB	  are	  among	  the	  most	  common	  reasons	  
for	  medical	  consultation	  (15)	  and	  have	  been	  found	  to	  be	  a	  major	  contributor	  to	  falls	  (7,	  
16-­‐18)	  and	  disability	  (19)	  in	  older	  adults.	  Interestingly,	  VDB	  is	  multifaceted	  and	  can	  be	  a	  
symptom	  from	  diagnosed	  vestibular	  diseases	  like	  benign	  paroxysmal	  positioning	  vertigo	  
(BPPV),	  be	  a	  consequence	  of	  aging	  systems	  in	  the	  body,	  or	  result	  from	  other	  conditions	  
such	  as	  cardiovascular	  diseases	   (20),	  hypotension	  (21),	  psychiatric	  conditions	   (22),	  or	  
medication	   (23,	   24).	   The	  physical	   impact	   of	   VDB	  on	   older	   people	   is	   often	  underrated.	  
Medication	  is	  of	  utmost	  importance	  because	  it	  is	  a	  modifiable	  risk	  factor,	  which	  should	  
be	  considered.	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With	  comorbidity	  comes	  a	  necessity	  for	  medication	  and	  vulnerability	  to	  prolonged	  drug	  
effects	   and	   increased	   risk	   to	   unwanted	   side	   effects	   in	   older	   people	   (25).	   Of	   specific	  
interest,	   are	   medications	   with	   anticholinergic	   and	   sedative	   (AS)	   effects	   as	   they	   may	  
negatively	   influence	   the	   health	   and	   well-­‐being	   of	   older	   people.	   Of	   concern	   in	   older	  
people,	   are	   the	   potential	   effects	   of	   AS	   medications	   like	   confusion,	   blurred	   vision,	  
delirium,	   or	   unsolicited	   central	   and	   peripheral	   adverse	   events	   (26)	   since	   these	  
medications	   are	   prescribed	   for	   a	   multitude	   of	   indications	   including	   urinary	  
incontinence,	   sleep	   disturbances,	   mental	   illness,	   pain,	   and	   cardiovascular	   and	  
gastrointestinal	   disorders	   (27).	   These	   medications	   can	   include	   antipsychotics,	  
antidepressants,	   and	   antihistamines,	   of	   which	   some	   have	   been	   deemed	   potentially	  
inappropriate	  for	  older	  people	  in	  Germany	  (28).	  
High	  uses	   of	  AS	  medications	   have	   been	   associated	  with	   reduced	   cognitive	   functioning	  
and	   functional	   impairments	   (27,	   29,	   30).	   Use	   of	   medicines	   with	   anticholinergic	  
properties	   was	   associated	   with	   complications	   in	   balance	   and	   mobility	   (26,	   31).	  	  
Sedatives	  have	  been	  connected	   to	  depressive	   symptoms,	   impaired	   cognition,	   impaired	  
muscle	   strength,	   falls	   and	   fractures	   (32-­‐36).	  With	   the	  goal	  of	   inevitably	  minimizing	  or	  
eliminating	   burdening	   medications	   in	   older	   people,	   a	   review	   of	   AS	   medications	   from	  
primary	  care	  practitioners	  (PCPs)	  could	  be	  beneficial	  (26),	  especially	  for	  VDB	  patients.	  	  
Research	  Question	  	  
This	   PhD	  project	   aimed	   to	   answer	   the	   following	   research	   question:	   Is	   exposure	   to	  AS	  
medications	  associated	  with	  an	  increased	  risk	  of	  VDB	  in	  older	  people	  in	  Germany?	  	  	  
Objectives	  
Specifically,	  the	  following	  objectives	  were	  targeted:	  
1. Develop	   a	   list	   of	   AS	   medications	   based	   on	   the	   German	   health	   care	   setting,	   which	  
allows	  for	  calculation	  and	  utilization	  of	  AS	  burden	  using	  the	  Drug	  Burden	  Index	  (DBI)	  
where	  applicable.	  
2. Examine	  the	  prevalence	  of	  AS	  burden	  and	  VDB	  prevalence	  	  
a. in	  a	  selected	  German	  patient	  population	  in	  the	  primary	  care	  setting	  and	  
b.  in	  an	  older	  German	  general	  population	  based	  setting.	  
3. To	  analyze	  the	  potential	  association	  of	  AS	  burden	  with	  VDB	  in	  these	  populations	  
a. in	  a	  nested	  matched	  case-­‐control	  study	  using	  primary	  care	  registry	  data	  and	  
b. in	  a	  cross-­‐sectional	  study	  using	  health	  survey	  data	  utilizing	  the	  DBI.	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Overview	  of	  the	  Doctoral	  Thesis	  
This	  doctoral	  thesis	  encompasses	  two	  scientific	  articles	  that	  were	  published	  in	  
international	  peer-­‐reviewed	  journals:	  	  
1. Phillips,	  Amanda;	  Strobl,	  Ralf;	  Grill,	  Eva;	  Laux,	  Gunter	  	  (2018).	  Anticholinergic	  
and	  sedative	  medications	  and	  the	  risk	  of	  vertigo	  or	  dizziness	  in	  the	  German	  
primary	  care	  setting-­‐A	  matched	  case-­‐control	  study	  from	  the	  CONTENT	  registry.	  
Pharmacoepidemiology	  and	  Drug	  Safety,	  Vol.	  27,	  Nr.	  8:	  P.	  912-­‐920,	  
https://doi.org/10.1002/pds.4575	  	  
	  
(referred	  to	  as	  “Publication	  1”	  in	  the	  succeeding	  text)	  
	  
2. Phillips,	  Amanda;	  Heier,	  Margit;	  Strobl,	  Ralf;	  Linkohr,	  Birgit;	  Holle,	  Ralf;	  Peters,	  
Annette;	  Grill,	  Eva	  (2019).	  Exposure	  to	  anticholinergic	  and	  sedative	  medications	  
using	  the	  Drug	  Burden	  Index	  and	  its	  association	  with	  vertigo,	  dizziness	  and	  
balance	  problems	  in	  older	  people	  –	  Results	  from	  the	  KORA-­‐FF4	  Study.	  
Experimental	  Gerontology,	  Vol.	  124C,	  2019,	  110644,	  
https://doi.org/10.1016/j.exger.2019.110644	  
	  
(referred	  to	  as	  “Publication	  2”	  in	  the	  succeeding	  text)	  
	  

















Publication	  1	   P 	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   P 	   	  
Publication	  2	   P 	   	   P 	   	   P 	  
	  
These	  articles	  represent	  a	  4.5-­‐year	  research	  process	  targeted	  to	  address	  the	  
aforementioned	  objectives	  and	  research	  question.	  	  
Methods	  
Data	  Source,	  Study	  Design	  and	  Participants	  
The	  research	  question	  and	  objectives	  were	  addressed	  using:	  	  
• Publication	  1:	  primary	  care	  based	  registry	  data	  from	  the	  German	  CONTENT	  
(CONTinuous	  morbidity	  registration	  Epidemiologic	  NeTwork)	  registry	  (2010-­‐
2014)	  	  
	  
• Publication	  2:	  cross-­‐sectional	  data	  from	  the	  second	  follow-­‐up	  of	  the	  KORA	  
(Cooperative	  Health	  Research	  in	  the	  Region	  of	  Augsburg)-­‐S4	  cohort	  study	  in	  
2014	  (KORA-­‐FF4)	  	  
6	  
CONTENT	  
The	  German	  CONTENT	  is	  a	  prospective	  registry	  based	  on	  primary	  care	  encounters	  in	  4	  
German	   federal	   states	   (Baden-­‐Württemberg,	   Hessen,	   Lower	   Saxony	   and	   Rhineland-­‐
Palatinate)	   and	   has	   been	   described	   in	   detail	   elsewhere	   (37,	   38).	   The	   registry	   is	  
maintained	  by	  the	  Department	  of	  General	  Practice	  and	  Health	  Services	  Research	  of	  the	  
University	  Hospital	  Heidelberg.	  Data	  used	  in	  this	  study	  were	  collected	  from	  just	  over	  1.8	  
million	   physician/patient	   encounters	   comprising	   routine	   claims	   data	   (diagnoses	   and	  
medications	  given	  on	  a	  specific	  consultation	  day)	  within	  the	  German	  primary	  healthcare	  
system	  between	  1.1.2010	  and	  31.12.2014.	  Vertigo	  or	  dizziness	  diagnoses	  were	  recorded	  
according	   to	   the	   International	   Classification	   of	   Diseases	   10th	   Revision	   (ICD-­‐10).	   The	  
participating	   PCPs	   are	   representative	   of	   practice	   size	   and	   location	   in	   Germany	   (39).	  
Ethical	   approval	   for	   the	   CONTENT	   project	   was	   given	   by	   the	   University	   Hospital	  
Heidelberg	  Ethics	  Committee	  (No.	  442-­‐2005).	  	  	  
	  
Electronic	  patient	  data	  from	  a	  total	  of	  151,446	  patients	  were	  screened.	  A	  VDB	  diagnosis	  
was	   identified	   in	   6,971	   (4.6%)	   patients	   (cases)	   and	   these	   cases	   were	   matched	   with	  
6,971	   corresponding	   controls	   using	   propensity	   score	   matching	   (40)	   to	   obtain	  
comparable	  cohorts.	  A	  nested	  matched	  case-­‐control	  study	  of	  n=6,971	  cases	  with	  a	  VDB	  
diagnosis	  and	  n=6,971	  controls	  without	  a	  VDB	  diagnosis	  were	  included	  in	  the	  analyses	  
of	  Publication	  1.	  
KORA-­‐FF4	  
Data	  originates	  from	  the	  Cooperative	  Health	  Research	  in	  the	  Region	  of	  Augsburg	  (KORA)	  
FF4	  study,	  the	  second	  follow-­‐up	  of	  the	  KORA	  S4	  study,	  a	  population-­‐based	  health	  survey	  
conducted	   in	   the	   city	   of	   Augsburg	   and	   two	   surrounding	   counties	   between	   1999	   and	  
2001.	  A	  total	  sample	  of	  6640	  subjects	  was	  drawn	  from	  the	  target	  population	  consisting	  
of	  all	  German	  residents	  of	  the	  region	  aged	  25	  to	  74	  years.	  	  
	  
Of	  all	  4261	  participants	  of	  the	  S4	  baseline	  study,	  2279	  also	  participated	  in	  the	  14-­‐year	  
follow-­‐up	   FF4	   study.	   The	   study	   was	   conducted	   from	   June	   2013	   to	   September	   2014.	  
Persons	  were	   considered	   ineligible	   for	   FF4	   if	   they	   had	   died	   in	   the	  meantime	   (n=455,	  
10.7%),	   lived	   too	   far	   outside	   the	   study	   region	   or	   were	   completely	   lost	   to	   follow-­‐up	  
(n=296,	  6.9%),	   or	  had	  demanded	  deletion	  of	   their	   address	  data	   (n=191,	  4.5%).	  Of	   the	  
remaining	  3319	  eligible	  persons,	  157	  could	  not	  be	  contacted,	  504	  were	  unable	  to	  come	  
because	  they	  were	  too	  ill	  or	  had	  no	  time,	  and	  379	  were	  not	  willing	  to	  participate	  in	  this	  
follow-­‐up,	   giving	   a	   response	   rate	   of	   68.7%.	   A	   non-­‐participant	   questionnaire	   was	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received	  from	  n=622	  people.	  Of	  the	  final	  2279	  participants,	  883	  were	  ≥65	  years	  old	  and	  
included	  in	  the	  analyses	  of	  Publication	  2.	  	  
The	  KORA-­‐FF4	  study	  collected	  variables	  through	  a	  telephone	  or	  face-­‐to-­‐face	  interview,	  
and	  direct	  measurements	   at	   the	   study	   center.	   The	   investigations	   and	   interviews	  were	  
carried	  out	   in	  accordance	  with	   the	  Declaration	  of	  Helsinki,	   including	  written	   informed	  
consent	  of	  all	  participants.	  The	  ethics	  committee	  of	  the	  Bavarian	  Chamber	  of	  Physicians,	  
Munich	  (EC	  No.	  06068),	  approved	  all	  study	  methods.	  
Conceptual	  Foundations	  
Individual-­‐level	  –	  Measuring	  AS	  Burden	  
A	  universally	  accepted	  list	  of	  AS	  medications	  is	  not	  currently	  available.	  Over	  the	  last	  15	  
years,	   there	   have	   been	   multiple	   efforts	   to	   define	   AS	   medications	   and	   their	   level	   of	  
burden	  (41-­‐44).	  The	  desire	  for	  one	  universally	  accepted	  list	  of	  AS	  medications	  is	  nearly	  
impossible	   due	   to	   the	   variability	   of	   prescription	   methods	   in	   primary	   care,	   dosage	  
recommendations,	  and	  medications	  on	  the	  market	  from	  country	  to	  country.	  This	  in	  turn	  
makes	   comparisons	   from	   scale	   to	   scale	   and	   population	   to	   population	   difficult	   to	  
interpret	  (45);	  nevertheless	  incorporating	  the	  prescribed	  dose	  was	  found	  to	  be	  the	  most	  
reliable	   in	   predicting	   anticholinergic	   adverse	   events	   (46).	   Therefore,	   applying	   and	  
interpreting	  research	  methods	  regarding	  AS	  burden	  needs	  to	  be	  directly	  related	  to	  the	  
population	  at	  risk	  and	  consider	  the	  prescribed	  dose.	  	  
First,	  a	  list	  of	  AS	  medications	  was	  compiled	  using:	  
• relevant	  published	  AS	  medication	  lists	  (42,	  47-­‐51)	  	  
• potentially	  inappropriate	  medications	  with	  AS	  effects	  from	  the	  German	  PRISCUS	  List	  (6)	  	  	  
• licensed	  product	  information	  collected	  in	  this	  study	  including	  Anatomical	  	  Therapeutic	  
Chemical	  Classification	  System	  (ATC-­‐Codes)	  (52,	  53)	  
	  
AS	  medications	  not	  available	  on	  the	  German	  market	  were	  not	  included	  in	  this	  list.	  This	  
list	   was	   then	   used	   as	   a	   basis	   to	   go	   a	   step	   further	   and	   employ	   the	   dose	   for	   each	   AS	  
medication	  as	  a	  measure	  of	  AS	  burden.	  	  	  
	  
In	  2007,	  Professor	  Sarah	  Hilmer	  created	  a	  pharmacological	   index,	   the	  DBI,	   to	  measure	  
exposure	   to	   anticholinergic	   and	   sedative	   medications	   (42)	   and	   their	   burden	   on	  
functioning	   in	  older	  adults	  and	  can	  be	  used	  worldwide	  (27,	  54).	  DBI	  scores	  have	  been	  
associated	  with	   functional	   impairment	   and	   other	   adverse	   outcomes	   in	   USA,	   Australia,	  
Finland,	   Ireland,	   the	   Netherlands,	   New	   Zealand,	   UK	   populations	   and	   recently	   in	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Germany	   (42,	   46-­‐48,	   50,	   51,	   54-­‐65).	   	   If	   validated	   in	   other	   specific	   populations	  
worldwide,	  this	  pharmacological	  tool	  has	  potential	  to	  provide	  an	  evidence-­‐based	  guide	  
for	  prescribing	  in	  older	  people	  (42,	  51,	  54).	  
First,	   the	   individual	  burden	  of	   each	  AS	  medication	   is	  weighted	  equally	   to	  determine	  a	  
score	   from	  0	   to	  1,	  with	  0.5	   indicating	   exposure	   at	   the	  prescribed	  daily	  dose.	  Then,	   all	  
individual	  AS	  medication	  DBI	  scores	  for	  each	  participant	  were	  summed	  for	  the	  total	  DBI	  
score	  using	  the	  following	  formula	  (42):	  
𝑫𝑩𝑰   = Ʃ
𝑫
𝜹 + 𝑫  
	  
where	  D	  denotes	   the	  prescribed	  daily	  dose	  of	  any	  AS	  medication,	  and	  δ	   is	   the	  defined	  
daily	   dose	   (DDD)	   of	   the	   individual	   drug	   according	   to	   German	   Institute	   of	   Medical	  
Documentation	   and	   Information	   (DIMDI)	   (53)	   to	   ensure	   all	   dosages	   pertain	   to	   the	  
German	  market.	  The	  DBI	  includes	  all	  regularly	  taken	  AS	  medications.	  Any	  medications,	  
which	   were	   topical,	   inhaled,	   or	   ophthalmological,	   as	   well	   as	   medications	   not	   taken	  
regularly	  were	  excluded	   in	  order	  to	   include	  only	  those	  medications	  where	  an	  accurate	  
DBI	  could	  be	  calculated.	  If	  a	  medication	  was	  classified	  as	  having	  both	  anticholinergic	  and	  
sedative	   effects,	   it	   was	   only	   included	   once	   in	   the	   DBI	   calculation	   (42,	   66).	   A	   DBI	   >0	  
demonstrates	  AS	  burden.	  The	  higher	  the	  DBI	  score,	  the	  more	  AS	  burden	  the	  participant	  
has.	  
	  
To	  measure	  the	  prevalence	  of	  AS	  burden,	  various	  classifications	  were	  applied	  according	  
to	   the	  data	   in	   each	  publication.	   In	  Publication	  1	  using	  CONTENT	  data,	   exposure	   to	  AS	  
medications	   was	   defined	   as	   patients	   having	   an	   AS	   medication	   prescription	   any	   time	  
within	   the	   study	  period	   (AS	  use).	  Patients	  who	  were	  not	  prescribed	  an	  AS	  medication	  
during	  the	  study	  period	  were	  regarded	  as	  having	  no	  AS	  use.	  Information	  regarding	  the	  
dosage,	   adherence,	   length	   of	   time	   medication	   was	   taken	   or	   if	   the	   medication	   was	  
changed	  or	  stopped,	  was	  not	  available	  in	  this	  dataset.	  Therefore,	  AS	  exposure	  could	  not	  
be	   quantified	   using	   the	   DBI,	   but	   instead	   AS	   use	   vs.	   no	   AS	   use	   was	   used	   to	   define	   AS	  
burden.	   In	   Publication	   2	   using	   KORA-­‐FF4	   data,	   the	   DBI	   could	   be	   calculated	   and	  
prevalence	  of	  AS	  burden	  (DBI	  >0)	  was	  estimated.	  
Population-­‐level	  -­‐	  Hypotheses	  on	  health	  outcomes	  
Primary	  Care	  Setting	  
	  
As	  mentioned	  before,	  PCPs	  are	  frequently	  visited	  by	  VDB	  patients.	  While	  there	  are	  
distinct	  vestibular	  and	  non	  vestibular	  etiologies	  of	  vertigo	  that	  can	  be	  addressed	  by	  
specific	  therapy,	  many	  VDB	  complaints	  remain	  under-­‐	  or	  misdiagnosed	  and	  as	  a	  result,	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are	  inaccurately	  accommodated	  in	  primary	  care	  (67).	  According	  to	  the	  International	  
Classification	  of	  Diseases	  10th	  Revision	  (ICD-­‐10)	  Codes,	  the	  following	  VDB	  related	  
diseases	  or	  symptoms	  were	  examined,	  when	  appropriate,	  in	  this	  thesis:	  
H81.0	  –	  “Meniere’s	  Disease”	  
H81.1	  –	  “Benign	  paroxysmal	  vertigo,	  unspecified	  ear”	  
H81.2	  –	  “Vestibular	  neuronitis,	  unspecified	  ear”	  
H81.3	  –	  “Other	  peripheral	  vertigo”	  
H81.4	  –	  “Vertigo	  of	  central	  origin”	  
H81.8	  –	  “Other	  disorders	  of	  vestibular	  function”	  
H81.9	  –	  “Disorder	  of	  vestibular	  function,	  unspecified”	  
R42	  –	  “Dizziness	  and	  giddiness”	  
	  
First	  identifying	  an	  accurate	  diagnosis,	  and	  second	  assigning	  a	  suitable	  therapy	  is	  quite	  a	  
challenge	  for	  PCPs	  (68-­‐70).	  It	  was	  recently	  seen	  in	  two	  primary	  care	  studies	  that	  87.2%	  
(67)	   and	   80.2%	   (69)	   of	   diagnoses	  were	   assigned	  with	   the	   ICD-­‐10	   Code	  R42,	  which	   is	  
very	  unspecific	  in	  nature.	  It	  is	  recommended	  that	  patients	  with	  unspecific	  or	  vestibular	  
VDB	   diagnoses	   should	   not	   be	   prescribed	   vestibular	   suppressants	  with	   AS	   effects	   as	   a	  
treatment	  option;	   instead	  an	   in-­‐depth	  medical	  patient	  history	  should	  be	  reviewed	  and	  
alternatives	   should	   be	   considered	   when	   possible	   (71,	   72).	   We	   know	   that	   vertigo	   or	  
dizziness	   may	   also	   be	   a	   direct	   side-­‐effect	   or	   adverse	   drug	   reaction	   to	   some	   AS	  
medications.	  However,	  polypharmacy	  (73)	  and	  potentially	   inappropriate	  combinations	  
of	  medications	  (24)	  have	  been	  shown	  to	  increase	  the	  risk	  of	  VDB.	  Therefore,	  to	  improve	  
the	   management	   of	   VDB	   patients	   in	   primary	   care,	   examining	   the	   utilization	   of	   a	  
potentially	   adjustable	   risk	   factor	   like	   AS	   medication	   for	   VDB	   disorders	   deserves	  
attention.	   Since	   older	   people	   are	   more	   susceptible	   to	   VDB,	   comorbidities,	   and	  
polypharmacy,	  caution	  should	  especially	  be	  taken	  in	  this	  age	  group.	  	  	  
Population-­‐based	  setting	  
Clinical	   diagnosis	   of	   VDB	   is	   problematic	   due	   to	   its	   multifactorial	   nature	   and	   the	  
perception	   of	   VDB	   is	   not	   easy	   for	   a	   patient	   to	   explain	   (74,	   75).	   	   Therefore,	   VDB	   as	   a	  
symptom	   often	   turns	   chronic	   or	   goes	   under-­‐	   or	   misdiagnosed.	   However,	   from	   the	  
individual’s	   perspective	   the	   lasting	   effects	   of	   VDB	   on	   mobility	   (76),	   injuries	   and	  
fractures	  (7),	  falls	  (7,	  16-­‐18),	  restrictions	  of	  social	  participation	  (77,	  78),	  disability	  (19),	  
and	  nursing	  care	  (79)	  still	  remain.	  Since	  the	  effects	  of	  VDB	  are	  still	  noticeable	  without	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having	   a	   specific	   diagnosis,	   self-­‐reported	   symptoms	   could	   be	   beneficial	   in	  
epidemiological	   research.	   Not	   only	   can	   this	   be	   measured	   in	   representative	   and	  
population-­‐based	   populations,	   self-­‐reported	   VDB	   still	   captures	   the	   true	   picture	   that	  
participants	   have	   suffered	   from	   VDB	   symptoms,	   regardless	   of	   their	   severity	   and	  
specificity	  (65).	  Self-­‐reported	  VDB	  in	  this	  thesis	  was	  assessed,	  when	  appropriate,	  using	  
standardized	   questions	   from	   the	   balance	   section	   of	   the	  National	  Health	   and	  Nutrition	  
Examination	  Survey	  2003-­‐2004	  (80).	  	  
Participants	  were	   asked	   about	   lifetime	   VDB,	   “Have	   you	   ever	   had	   vertigo,	   dizziness	   or	  
difficulty	  with	  balance?”	  If	  the	  answer	  was	  “Yes”,	  it	  was	  followed	  by	  a	  separate	  question	  
on	  12-­‐month	  VDB,	  “In	   the	   last	  12	  months,	  have	  you	  had	  vertigo,	  dizziness	  or	  difficulty	  
with	  balance?”	  Presence	  of	  VDB	  was	  defined	  as	  answering	  “Yes”	  to	  both	  lifetime	  and	  12-­‐
month	  VDB	  questions.	  
	  
Statistical	  Analyses	  
In	  Publication	  1,	  descriptive	  statistics	  were	  used	  to	  describe	  differences	  between	  cases	  
and	  controls	  using	  t-­‐tests	  for	  continuous	  variables	  and	  chi-­‐squared	  tests	  for	  categorical	  
variables.	  Adjusted	  matched	  odds	  ratios	  (AOR)	  and	  95%	  confidence	  intervals	  (CI)	  were	  
calculated	   using	   a	  multivariable	   conditional	   logistic	   regression	  model	   to	   approximate	  
the	   risk	   of	   vertigo	   or	   dizziness	   in	   AS	   use	   versus	   no	   AS	   use,	   adjusted	   for	   potential	  
confounding	   factors.	   Sensitivity	   analyses	   were	   conducted	   looking	   at	   associations	  
between	  1)	  AS	  use	  within	  1	  year	  before	  and	  2)	  within	  60	  days	  after	  a	  VDB	  diagnosis	  to	  
mimic	  a	  cause-­‐effect	  relationship	  and	  have	  a	  look	  into	  prescription	  patterns	  after	  a	  VDB	  
diagnosis.	  	  
In	   Publication	   2	   using	   KORA-­‐FF4	   data,	   the	   prevalence	   of	   AS	   burden	   (DBI	   >0)	   was	  
estimated,	  as	  well	  as,	   stratified	  by	  sex	  and	  age	  groups	   in	   those	  with	  and	  without	  VDB.	  	  
Adjusted	   odds	   ratios	   (AOR)	   and	   95%	   confidence	   intervals	   (95%	   CI)	   were	   computed	  
using	  multivariable	  logistic	  regression	  analysis	  to	  estimate	  the	  risk	  of	  VDB	  in	  those	  with	  
a	  DBI	  >0	  (AS	  burden)	  versus	  no	  DBI	  (no	  AS	  burden).	  Furthermore,	  sensitivity	  analyses	  
yielded	   similar	   results	   using	   1)	   a	   higher	   DBI	   cut-­‐off	   value,	   2)	   a	   subgroup	   analysis	   of	  
those	  with	  a	  DBI	  >0	  on	  a	  continuous	  scale	  including	  a	  chi-­‐square	  test	  for	  trend,	  and	  3)	  a	  
model	  adjusting	  for	  all	  co-­‐morbidities	  which	  would	  minimize	  the	  likelihood	  that	  positive	  
associations	  between	  AS	  burden	  and	  VDB	  are	  due	  to	  the	  treatment	  of	  multiple	  diseases	  
with	  multiple	  medications.	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Main	  Results	  and	  Scientific	  Contribution	  
Publication	  1	  
	  
AS	  and	  VDB	  prevalence	  in	  the	  German	  primary	  care	  setting	  (Publication	  1):	  	  
Out	  of	  151,446	  patients,	  6971	  cases	  (4.6%)	  were	  diagnosed	  with	  at	  least	  one	  vertigo	  or	  
dizziness	  diagnosis	  between	  the	  study	  period	  2010-­‐2014.	  Cases	  had	  10,552	  consultation	  
days	   with	   at	   least	   1	   vertigo	   or	   dizziness	   diagnosis.	   AS	  medication	  was	   prescribed	   on	  
1,072	  of	  10,552	  (10.2%)	  days	  of	  vertigo	  or	  dizziness	  diagnoses.	  Dizziness	  and	  giddiness	  
(ICD-­‐10	   Code	   R42)	   was	   diagnosed	   most	   often	   (87.2%)	   by	   PCPs,	   followed	   by	   BPPV	  
(6.7%)	  (ICD-­‐10	  Code	  H81.1).	  a	  higher	  prevalence	  of	  AS	  prescriptions	  was	  seen	  in	  cases	  
with	  vertigo	  or	  dizziness	   (63.4%)	   compared	  with	   controls	   (42.2%)	  without	  vertigo	  or	  
dizziness,	  especially	  in	  cases	  aged	  ≥	  65	  years	  old	  (71.2%)	  compared	  with	  controls	  aged	  
≥	  65	  years	  old	  50.9%	  (67).	  	  
Association	  of	  AS	  use	  and	  VDB	  in	  the	  German	  primary	  care	  setting	  (Publication	  1):	  
Using	  a	  matched	  case-­‐control	  design	  on	  a	  complete	  survey	  of	  primary	  care	  prescriptions	  
in	  Germany,	  we	   found	   that	   after	   adjusting	   for	   covariates,	   a	   significant	   association	  was	  
seen	  between	  AS	  medication	  use	   and	   a	  higher	   risk	   of	   vertigo	  or	  dizziness	   (AOR:	   1.37,	  
95%	  CI:	  1.18-­‐1.58,	  P	  <	  0.001).	  Additionally,	  sensitivity	  analyses	  were	  conducted	  looking	  
at	  associations	  between	  1)	  AS	  use	  within	  1	  year	  before	  (AOR:	  1.61,	  95%	  CI:	  1.36-­‐1.92,	  P	  
<	  0.001),	  or	  2)	  within	  60	  days	  after	  a	  VDB	  diagnosis	  (AOR:	  1.18,	  95%	  CI:	  1.09-­‐1.28,	  P	  <	  
0.001),	  of	  which	  both	  analyses	  yielded	  similar	  results.	  	  
The	  scientific	  contribution	  of	  Publication	  1	  is	  summarized	  in	  Box	  1.	  
Box	  1:	  Scientific	  Contribution	  of	  Publication	  1	  
	  
• AS	  medication	  use	  was	  higher	  in	  cases	  with	  vertigo	  or	  dizziness	  than	  in	  controls	  
without	  vertigo	  or	  dizziness,	  highlighting	  the	  persistent	  prescribing	  of	  AS	  medication	  
to	  vertigo	  or	  dizziness	  patients	  although	  these	  medications	  could	  be	  aggravating	  
symptoms.	  
	  
• AS	  use	  was	  more	  prevalent	  in	  older	  cases	  compared	  to	  older	  controls.	  Caution	  should	  
be	  taken	  when	  prescribing	  AS	  medications	  to	  older	  adults	  (≥65	  years	  old).	  Systematical	  
calculations	  of	  AS	  medication	  burden	  could	  help	  acknowledge	  this	  issue	  and	  raise	  
awareness	  for	  prescription	  habits	  in	  primary	  care.	  
	  
• AS	  medication	  use	  was	  associated	  with	  a	  higher	  risk	  of	  vertigo	  or	  dizziness	  suggesting	  
AS	  medication	  has	  the	  potential	  to	  contribute	  to	  the	  burden	  of	  disease.	  PCPs	  should	  
consider	  AS	  medication	  as	  a	  risk	  factor	  for	  vertigo	  or	  dizziness.	  
	  
• Vertigo	  and	  dizziness	  diagnoses	  in	  our	  study	  were	  rather	  unspecific	  which	  underlies	  
the	  lack	  of	  accurate	  diagnoses	  and	  a	  need	  for	  PCP	  vertigo/dizziness	  expertise	  in	  the	  
German	  primary	  care	  setting.	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Publication	  2	  
AS	  and	  VDB	  prevalence	  in	  an	  older	  German	  general	  population	  (Publication	  2):	  	  
Out	   of	   883	   older	   participants,	   257	   (29.1%)	   reported	   having	   VDB	   during	   the	   last	   12	  
months.	  AS	  burden	   (DBI	  >0)	  was	  higher	   in	   those	  with	  VDB:	  27.6%	  compared	   to	   those	  
without	  VDB	  (15.3%)	  (p	  <	  0.001).	  Higher	  AS	  burden	  (DBI	  >	  0.5)	  was	  also	  seen	  in	  those	  
with	  VDB	  (10.9%)	  compared	  to	  those	  without	  (4.0%).	  In	  particular,	  those	  with	  VDB	  and	  
≥80	  years	  old	  had	  a	  higher	  prevalence	  of	  AS	  burden	  compared	  to	  those	  without	  VDB	  in	  
the	   same	   age	   group	   (44.8%	   vs.	   16.8%).	   Independent	   of	   VDB,	   overall	   AS	   burden	   was	  
present	   in	   18.9%	   of	   participants,	  with	   highest	   prevalence	   of	   AS	   burden	   seen	   in	   those	  
≥80	  years	  old	  (26.3%).	  
Association	  of	  AS	  use,	  using	  the	  DBI,	  with	  VDB	  and	  falls	  in	  an	  older	  German	  
general	  population	  (Publication	  2):	  
After	  adjustment	  of	  clinically	  relevant	  confounders,	  this	  multivariable	  logistic	  regression	  
analysis	   from	   a	   large	   population-­‐based	   sample	   in	   Germany	   identified	   a	   significant	  
association	  between	  AS	  burden	  (AOR:	  1.73	  [95%	  CI,	  1.16–2.56]),	  age	  (AOR:	  1.03,	  [95%	  
CI,	   1.00–1.05]),	   sex	   (AOR:	   1.95,	   [95%	   CI,	   1.43–2.66]),	   insomnia	   (AOR:	   2.53,	   [95%	   CI,	  
1.44–4.45]),	  and	  Parkinson’s	  disease	  (AOR:	  4.06,	   [95%	  CI,	  1.37–13.67])	  and	  VDB.	  Most	  
notably,	   sensitivity	   analyses	   revealed	   a	   DBI	   >0.5	   (AOR:	   2.27,	   [95%	   CI,	   1.18-­‐4.36])	  
compared	  to	  no	  DBI	  was	  significantly	  associated	  with	  VDB.	  Moreover,	  a	  chi-­‐squared	  test	  
for	  trend	  (p<	  0.001)	  indicated	  a	  linear	  increase	  in	  proportions	  of	  VDB	  cases	  as	  the	  DBI	  
category	  increased	  by	  0.5.	  
The	  scientific	  contribution	  of	  Publication	  2	  is	  summarized	  in	  Box	  2.	  
Box	  2:	  Scientific	  Contribution	  of	  Publication	  2	  
	   	  
• Prevalence	  of	  AS	  burden	  (DBI	  >0)	  was	  high	  in	  the	  general	  aging	  population,	  especially	  
in	  those	  with	  VDB	  and	  ≥80	  years	  old.	  	  These	  results	  highlight	  the	  importance	  of	  
monitoring	  AS	  medication	  use	  in	  older	  age	  groups,	  specifically	  those	  with	  VDB	  
symptoms,	  since	  they	  are	  a	  possible	  contributing	  factor	  that	  should	  be	  avoided.	  	  
	  
• We	  found	  AS	  burden	  to	  be	  significantly	  and	  independently	  associated	  with	  VDB.	  These	  
finding	  suggest	  that	  AS	  medications	  used	  in	  the	  calculation	  of	  the	  DBI	  could	  contribute	  
to	  the	  burden	  of	  VDB	  and	  despite	  several	  evidence	  based	  regulations	  and	  guidelines	  for	  
avoiding	  AS	  use	  in	  older	  adults,	  this	  issue	  still	  warrants	  attention	  in	  health	  care.	  
	  
• The	  calculation	  of	  AS	  burden,	  for	  example	  using	  the	  DBI,	  could	  be	  helpful	  as	  a	  routine	  
risk	  assessment	  in	  ambulatory	  medical	  care.	  	  
13	  
Strengths	  and	  Limitations	  
Many	   strengths	   and	   some	   limitations	   were	   faced	   in	   the	   compilation	   of	   this	   doctoral	  
thesis	  work.	  Although	  VDB	  is	  a	  common	  complaint	  in	  community	  dwelling	  and	  in	  many	  
patient	   specific	  populations,	   as	  mentioned	  before	   its	  diagnosis	  and	  prognosis	  are	  very	  
complex.	  With	  many	  cases	  going	  under-­‐	  or	  misdiagnosed,	  evaluating	  both	  self-­‐reported	  
and	   confirmed	   diagnoses	   of	   VDB	   in	   nature	  was	   a	   key	   strength	   of	   this	   doctoral	   thesis	  
work.	  Self-­‐reported	  VDB	  could	  lead	  to	  a	  misrepresentation	  of	  self-­‐observation,	  however	  
it	   actually	   captures	   the	   true	   picture	   in	   reality	   that	   many	   suffer	   from	   VDB	   symptoms	  
although	   not	   officially	   diagnosed.	   When	   investigating	   specific	   VDB	   diagnoses	   in	   the	  
primary	  care	  setting	  there	  are	  two	  major	  advantages.	  One,	  we	  could	  evaluate	  how	  PCPs	  
diagnose	  such	  a	  difficult	  to	  handle	  and	  complex	  disease	  and	  second,	  we	  could	  examine	  
how	  AS	  medications	   play	   a	   role	   in	   prescription	   patterns	   and	   occurrence	   of	   diagnosed	  
VDB.	  	  
Furthermore,	  no	  universally	  accepted	  list	  of	  AS	  medications	  currently	  exists.	  This	  was	  a	  
challenge	   to	  compile	  a	  German-­‐specific	   list	  of	  AS	  medications	  and	   their	  corresponding	  
dosages.	   However,	   consensus	   lists	  were	   used	   from	   existing	  DBI	   literature	   (47-­‐51,	   59)	  
and	  German	  dosages	  according	  to	  DIMDI	  (53)	  were	  utilized	  in	  gathering	  an	  appropriate	  
AS	  medication	  list	  to	  use	  in	  this	  doctoral	  thesis	  on	  German	  populations.	  Additionally,	  we	  
used	   the	   DDD	   when	   calculating	   DBI	   scores	   in	   place	   of	   the	   recommended	   minimum	  
licensed	  daily	  dose	  (MDD)	  (81)	  based	  on	  the	  availability	  of	   licensed	  medicinal	  product	  
information	  in	  Germany.	  The	  DDD	  is	  much	  higher	  than	  the	  MDD	  for	  some	  drugs,	  but	  not	  
all	   (81)	   and	   has	   been	   considered	   as	   an	   alternative	   approach	   to	   be	   used	   in	   different	  
populations	  (58,	  81).	  With	  this	  being	  said,	  a	  more	  conservative	  approach	  in	  calculating	  
AS	  burden	  using	   the	  DBI	  was	   applied	   and	   estimates	   could	  have	  been	  underestimated.	  
Nevertheless,	   associations	   were	   found	   between	   AS	   burden	   and	   VDB	   in	   this	   doctoral	  
thesis	  work.	  	  	  	  
Moreover,	  both	  analyses	  confronted	  the	  task	  of	  covariate	  selection	  by	  implying	  different	  
methods.	  The	  main	  goal	  was	  to	  minimize	  confounding	  and	  ensure	  clear	  interpretability	  
and	   comparability	   of	   the	   results.	   	   In	   Publication1,	   cases	   and	   controls	   were	   matched	  
using	   propensity	   scores	   based	   on	   significant	   determinants	   of	   VDB	   in	   order	   to	   obtain	  
comparable	   cohorts.	   Then	   a	   directed	   acyclic	   graph	   (DAG)	   was	   employed	   to	   identify	  
potential	  confounders	  as	  a	  minimal	  adjustment	  set	  of	  covariates	  needed	  to	  estimate	  the	  
effect	   of	   AS	   use	   on	   VDB	   (82).	   In	   Publication2,	   potential	   confounders	   that	   could	  
potentially	   influence	   the	   association	   of	   AS	   burden	   and	   VDB	   were	   chosen	   based	   on	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existing	   DBI	   literature	   to	   increase	   comparability	   to	   other	   studies.	   Both	   publications	  
investigated	   possible	   effect	   modification	   by	   testing	   possible	   appropriate	   interaction	  
effects,	  which	  were	  included	  in	  the	  models	  when	  significant.	  	  	  	  
Due	   to	   the	   case-­‐control	   and	   cross-­‐sectional	   study	   designs	   of	   Publication1	   and	  
Publication2	  in	  this	  doctoral	  thesis,	  we	  cannot	  claim	  any	  causal	  relationship	  between	  AS	  
burden	  and	  VDB;	  rather	  we	  can	  only	  assume	  associations.	  However,	  the	  data	  sources	  in	  
this	   doctoral	   thesis	   work	   allowed	   for	   analyses	   in	   two	   important	   settings	   when	  
considering	  AS	  burden	  and	  VDB;	  namely	  the	  primary	  care	  and	  real-­‐world	  perspectives.	  
The	   CONTENT	   dataset	   provided	   registry	   data	   over	   a	   5-­‐year	   time	   span	   from	   over	  
150,000	  VDB	  patients	  to	  investigate	  AS	  burden	  in	  a	  specific	  context,	  while	  quality	  data	  
from	   the	   large	   national	   population-­‐based	   KORA-­‐FF4	   dataset	   allowed	   for	   a	   more	  
generalizable	  interpretation	  of	  results.	  	  
Finally,	  a	  main	  strength	  of	  this	  doctoral	  thesis	  work	  was	  the	  sensitivity	  analyses,	  which	  
attempted	   to	   analyze	   the	   objectives	   from	   all	   different	   angles.	   In	   Publication1,	   time	  
played	  an	   important	   role	   in	  how	   to	   interpret	   the	   results.	  Therefore,	  we	  also	   tested	  AS	  
use	  strictly	  before	  a	  VDB	  diagnosis	  and	  conversely	  examined	  if	  a	  VDB	  diagnosis	  lead	  to	  
AS	  prescriptions	  within	  60	  days	  after	  the	  diagnosis.	  Both	  of	  which	  yielded	  higher	  risks.	  
In	  Publication2,	  a	  higher	   threshold	  of	  AS	  burden	  using	  other	  DBI	  score	  cut-­‐offs,	  a	  sub-­‐
group	   analyses	   of	   only	   those	   with	   AS	   burden	   (DBI>0)	   to	   examine	   a	   possible	   dose-­‐
response	   relationship,	   and	   a	  model	   controlling	   for	   all	   comorbidities	  were	   assessed	   in	  
order	   to	   test	   the	   robustness	   of	   our	   results.	   These	   further	   analyses	   give	   additional	  
perspectives	   on	   our	   underlying	   results	   and	   allowed	   for	   a	  well-­‐rounded	   testing	   of	   the	  
objectives	  at	  hand.	  	  	  	  	  	  
	  
Outlook	  of	  Doctoral	  Thesis	  
	  
This	  research	  set	  out	  to	  identify	  AS	  burden	  and	  VDB	  prevalence	  and	  associations	  in	  both	  
the	   German	   primary	   care	   and	   population	   based	   setting.	   	   Based	   on	   two	   quantitative	  
scientific	  analyses	  (Publication1	  and	  Publication2),	  it	  can	  be	  concluded	  that	  AS	  burden	  is	  
an	   important	   factor	   to	   consider	   when	   evaluating	   and	   diagnosing	   VDB.	   The	   results	  
indicate	   that	   potential	   strategies	   designed	   to	   target	   this	   patient-­‐population	   should	  
unequivocally	  include	  AS	  burden	  measurement	  and	  evaluation.	  	  
	  
This	  doctoral	  thesis	  clearly	  indicates	  a	  strong	  association	  between	  AS	  burden	  and	  VDB,	  
but	  it	  also	  opens	  the	  question	  of	  long-­‐term	  effects	  and	  trajectories.	  To	  better	  realize	  the	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implications	   of	   these	   results,	   future	   research	   could	   address	   the	   cause	   and	   effect	  
relationship	   between	   changes	   of	   AS	   burden	   and	  VDB	   or	   explore	   prevention	   efforts	   to	  
minimize	   AS	   burden	   and	   report	   the	   effects	   on	   patient	   populations.	   To	   date,	   very	   few	  
randomized-­‐controlled	  trials	  (RCT)	  have	  been	  conducted	  investigating	  AS	  burden,	  using	  
the	  DBI,	   and	   the	   effects	   its	   reduction	  has	   in	   susceptible	   older	  populations	   (83,	   84).	   In	  
fact,	   no	   RCT	   or	   longitudinal	   study	   has	   been	   performed	   in	   such	   a	   vulnerable	   patient	  
population	  like	  those	  with	  VDB.	  While	  our	  cross-­‐sectional	  analyses	   limits	  the	  temporal	  
causation	   aspect	   of	   the	   results,	   this	   approach	   offers	   insight	   into	   the	   future	   research	  
strategies	  regarding	  AS	  burden	  in	  older	  patient	  populations.	  	  	  	  	  
	  
In	  conclusion,	  implications	  from	  the	  analyses	  in	  this	  doctoral	  thesis	  are	  that	  health	  care	  
professionals	  should	  consider	  AS	  medications	  as	  an	  important,	  yet	  modifiable	  risk	  factor	  
for	  VDB.	   Caution	   should	   be	   taken	  when	  prescribing	   these	  medications	   to	   older	   adults	  
due	  to	  their	  sensitivity	  to	  their	  side-­‐effects	  and	  for	  the	  potential	  that	  these	  medications	  
could	  increase	  the	  risk	  of	  VDB	  or	  further	  aggravate	  existing	  symptoms.	  Translation	  into	  
practice	  could	  be	  realized	  through	  the	  calculation	  of	  AS	  burden	  in	  ambulatory	  care	  as	  a	  
routine	  risk	  assessment	  and	  applied	  within	  existing	  multidisciplinary	  medication	  review	  
services	   (65,	   81).	   As	   the	   world	   age	   and	   average	   life	   expectancies	   increase,	   attention	  
needs	  to	  be	  brought	  to	  a	  conceivable	  solution	  to	  maximize	  the	  quality	  of	  those	  years	  and	  
maintain	  health	  in	  older	  people.	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